CHEMICAL COMPOUNDS

Details for Australian Patent Application No. 2002246728 (hide)

Owner LILLY ICOS LLC

Inventors SIERRA, Michael; GOSMINI, Roamin, Luc, Marie; SAWYER, Jason, Scott; ORME, Mark, W.; BOMBRUN, Agnes; BOUILLOT, Anne; DODIC, Nerina

Pub. Number AU-A-2002246728

PCT Pub. Number WO2002/064590

Priority 60/268,158 12.02.01 US

Filing date 18 December 2001

Wipo publication date 28 August 2002

International Classifications

C07D 471/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 031/437

A61P 009/00 Drugs for disorders of the cardiovascular system

A61P 015/10 Drugs for genital or sexual disorders

C07D 519/00 Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Event Publications

20 February 2003 Application Open to Public Inspection

  Published as AU-A-2002246728

12 February 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002246729-NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

2002246727-SITE-SPECIFIC IN SITU GENERATION OF ALLICIN USING A TARGETED ALLIINASE DELIVERY SYSTEM FOR THE TREATMENT OF CANCERS, TUMORS, INFECTIOUS DISEASES AND OTHER ALLICINSENSITIVE DISEASES